Amgen EPO Patent Win Over Roche Could Derail Mircera Launch

 
• By Brenda Sandburg

Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.

More from Archive

More from Pink Sheet